CDK4/6 inhibition in metastatic ILC versus NST BC: comparison of PFS and OS

Dr Karen Van Baelen from University Hospitals Leuven presents research by Dr. Bauters on CDK4/6 inhibition in metastatic breast cancer patients. The study compared patients with ILC and NST receiving CDK4/6 inhibition in different treatment lines. Although PFS was similar in both cohorts, NST patients showed better outcomes when treated in the first line, unlike ILC patients. The data suggest that delaying CDK4/6 inhibition in ILC patients may not be detrimental if contraindicated in the first line. OS did not differ significantly. Multivariate analysis highlighted that endocrine resistance, rather than histological subtype, predicts the efficacy of CDK4/6 inhibition.

Reference:

Bauters C, The effect of histological breast cancer subtype on progression free survival in patients with CDK4/6 inhibitors. SABCS 2023, #PO3-05-05